Hydrochloric Acid

Hydrochloric Acid

SCHEMBL272675

CC(C)CC1=Cc2c(-c3cccc4ccccc34)cccc2C1[Zr](C)(C)(=[SiH2])C1C(CC(C)C)=Cc2c(-c3cccc4ccccc34)cccc21.Cl.Cl

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.30
MAPT P10636 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
ALOX5 P09917 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL273189 0.87 SLC6A4 (0.33)
SCHEMBL7188586 0.85 SLC6A4 (0.33)
Hydrochloric Acid SCHEMBL6065689 0.85
Hydrochloric Acid SCHEMBL272443 0.85 SLC6A4 (0.34)
SCHEMBL5582114 0.83 SLC6A4 (0.34)
SCHEMBL1241326 0.83 SLC6A4 (0.30) NPC1MAPTRAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL3679145 0.83 CNR1 (0.34)
SCHEMBL5951466 0.83 NPC1 (0.32) NPC1MAPTRAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL2513912 0.82 MAPT (0.32) NPC1MAPTRAB9ASMN1; SMN2ALOX5
SCHEMBL5890554 0.82 NPC1 (0.32) NPC1MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618912-B2 Preparation of supported catalyst systems BASELL POLYOLEFINE GMBH (DE) 2009-11-17 US claimed
US-20060166813-A1 Preparation of supported catalyst systems BASELL POLYOLEFINE GMBH (DE) 2006-07-27 US claimed
EP-2576642-B1 PROCESS FOR PREPARING A SUPPORTED CATALYST SYSTEM FOR OLEFIN POLYMERIZATION, THE CATALYST SYSTEM AND ITS USE BASELL POLYOLEFINE GMBH (DE) 2017-08-16 EP disclosed
EP-1824888-B1 MONOCYCLOPENTADIENYL COMPLEXES BASELL POLYOLEFINE GMBH (DE) 2017-01-18 EP disclosed
US-8999875-B2 Process for preparing a supported catalyst system for olefin polymerization, the catalyst system and its use BASELL POLYOLEFINE GMBH (DE) 2015-04-07 US disclosed
EP-1740626-B1 CATALYST SYSTEM FOR OLEFIN POLYMERIZATION, ITS PRODUCTION AND USE BASELL POLYOLEFINE GMBH (DE) 2014-10-22 EP disclosed
US-8859451-B2 Process for the preparation of supported catalysts BASELL POLYOLEFINE GMBH (DE) 2014-10-14 US disclosed
US-8664140-B2 Catalyst system for olefin polymerization, its production and use BASELL POLYOLEFINE GMBH (DE) 2014-03-04 US disclosed
EP-2576642-A2 PROCESS FOR PREPARING A SUPPORTED CATALYST SYSTEM FOR OLEFIN POLYMERIZATION, THE CATALYST SYSTEM AND ITS USE Basell Polyolefine GmbH (DE) 2013-04-10 EP disclosed
US-20130072652-A1 Process for preparing a supported catalyst system for olefin polymerization, the catalyst system and its use BASELL POLYOLEFINE GMBH (DE) 2013-03-21 US disclosed
US-8399536-B2 Irradiated polyolefin composition comprising a non-phenolic stabilizer Basell Poliolefine Italia, s.r.l. (IT) 2013-03-19 US disclosed
US-20040176624-A1 Reduction of concentration of inorganic by-products and organometallic by-products in the preparation of metallocenes and economical recovery of the starting materials used EQUISTAR CHEMICALS, LP 2004-09-09 US disclosed
WO-2004056482-A1 MONOCYCLOPENTADIENYL COMPLEXES BASELL POLYOLEFINE GMBH (DE) 2004-07-08 WO disclosed
WO-2004056481-A1 MONOCYCLOPENTADIENYL COMPLEXES BASELL POLYOLEFINE GMBH (DE) 2004-07-08 WO disclosed
WO-2004055070-A1 PREPARATION OF SUPPORTED CATALYST SYSTEMS CONTAINING REDUCED AMOUNTS OF ALUMINOXANES BASELL POLYOLEFINE GMBH (DE) 2004-07-01 WO disclosed
WO-2004020479-A2 MONOCYCLOPENTADIENYL COMPLEXES BASELL POLYOLEFINE GMBH (DE) 2004-03-11 WO disclosed
WO-2004018489-A1 MONOCYCLOPENTADIENYL COMPLEXES BASELL POLYOLEFINE GMBH (DE) 2004-03-04 WO disclosed
US-20030176275-A1 Catalytic solid supported on calcined hydrotalcite for olefinic polymerisation BASELL POLYOLEFINE GMBH (DE) 2003-09-18 US disclosed
US-20030055179-A1 Olefin block copolymers processes for producing the same and uses thereof MITSUI CHEMICALS, INC. (JP) 2003-03-20 US disclosed
EP-1275670-A1 OLEFIN BLOCK COPOLYMERS, PRODUCTION PROCESSES OF THE SAME AND USE THEREOF Mitsui Chemicals, Inc. (JP) 2003-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176624-A1 Reduction of concentration of inorganic by-products and organometallic by-products in the preparation of metallocenes and economical recovery of the starting materials used AS3MT, DNMT1, OSGEP NPC1 3081/4885MAPT 729/4885RAB9A 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.